Jerome Groopman discusses the results of a trial described in the New England Journal of Medicine, in which twenty-two patients with beta thalassemia, a common and devastating blood disorder, were treated with gene therapy.

The biotechnology sector’s fastest-growing segment, immuno-oncology, has become the hottest buzzword for investment in Asia.

The field, that uses the body’s own immune system to help fight cancer, has seen two mega acquisitions in the United States in recent months.

And Hong Kong stock exchange is now tuning into its strong future, with Hong Kong Exchanges and Clearing (HKEX) already agreeing to revamp listing rules that will fast track applications by firms linked with the sector to help more innovative drugs and medical devices developers go public as soon as early this summer, and raise much-needed development cash.

I t has now been decades since stem cell technology emerged as the next great breakthrough in modern medicine, with the bold potential for one day curing everything from heart disease to cancer. Today, that optimism doesn’t appear to have diminished.

It’s easy to recall the excitement. In the late 1990s, when stem cell research was still relatively unexplored but gathering pace, the hope surrounding future uses for such treatments appeared near limitless. Once greater advances had been made, it was often argued, doctors could one day inject patients with cells that have the ability to transform into any other type of cell, making it possible to grow whole new organs. In theory, any damaged area…